I recently purchased _A Walk In the Woods _by Bill Bryson. It's about two middle-aged, overweight men who decide to hike the Appalachian Trail. I'm...
Read The Full Article:
http://www.obesitydiscussion.com/forums/off-topic/a-walk-woods-book-report-19486.
html
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!I've been having issues with the pages loading - they 'jerk' to the top 3-4 times as I try and scroll down to the last post, etc. It's just annoying....
Read The Full Article:
http://www.obesitydiscussion.com/forums/website-suggestions-user-requests/quirky-
page-loading-issue-smilies-19484.html
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!
LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its top new drug hopes, has been recommended for use in the state health service after a change of heart by the country's healthcare cost-effectiveness watchdog.Friday's verdict from the National Institute for Health and Clinical Excellence (NICE), whose opinions are also watched closely in other countries, is welcome news for a product that has run into problems recently.Later on Friday, the European Medicines Agency (EMA) - the body responsible for licensing Gilenya in Europe in March 2011 - is expected to give an update on the safety of the medicine, following an in-depth review.The safety probe was launched because of reports of heart problems in some patients and the death of one person in the United States within 24 hours of starting treatment.Gilenya represents a significant change in multiple sclerosis (MS) treatment, since existing drugs such as beta interferons and Elan and Biogen Idec's Tysabri must be injected.NICE initially said it was unclear if the new drug, which is known generically as fingolimod, was any better than existing treatments.It changed its mind after Novartis presented data showing the benefits of using Gilenya in a subgroup of adults with highly active disease, whose relapses had increased or stayed the same compared with the previous year despite them taking beta interferons.Carole Longson, director of NICE's health technology evaluation centre, said it was now clear that Gilenya was a cost-effective option for these patients, provided Novartis supplied the drug at the discounted price it previously suggested.A NICE spokeswoman said the size of the discount remained confidential. The list price for 28 capsules is 1,470 pounds ($2,300) or just over 19,000 pounds per person for a year.Novartis and Britain's MS Society welcomed the final NICE decision, which is expected to be officially published next month.Gilenya's convenient dosing and encouraging results in clinical trials are widely expected to make it a popular alternative to current injections.The average forecast from analysts suggests global sales will reach $2 billion a year by 2015, according to Thomson Reuters Pharma.Gilenya is the first MS pill of its kind, but competitors in development include BG-12 from Biogen, teriflunomide from Sanofi and laquinimod from Teva.(Editing by David Holmes)
By Ben Hirschler | Reuters ? Fri, Mar 16, 2012 UK Yahoo News
Comments are appreciated. Note that All comments are moderated If not yet receiving our weekly e-Newsletter - Click here to: REGISTER -~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
..............................
Read The Full Article:
http://wwwmsviewsandrelatednews.blogspot.com/2012/03/uk-ms-news-update-cost-body-
backs.html
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!The link between migraines and pregnancy has been observed for quite some time now. Women without any prior history of migraines can suddenly find themselves experiencing splitting headaches. Migraines and pregnancy can be quite a difficult ailment to deal with. While pregnancy can contribute to migraines, typical headache cures can’t always be used due to [...]
Read The Full Article:
http://www.fitnesstipsforlife.com/migraines-and-pregnancy.html
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!On our Lab Notes page CalorieLab’s editors select and rank the day’s essential health news items in real time. Readers can suggest, vote and comment on items. Below are brief summaries of yesterday’s (March 16, 2012) Lab Notes items. To see today’s items, visit Lab Notes.
Obesity may significantly increase death risk tied to sleeping pills.
Kirsten Haglund, crowned Miss America when she was 19 in 2008, suffered from anorexia nervosa at the age of 12 as she struggled to fulfill her dream of becoming a ballerina.
Only about half of stroke patients call 911 for emergency help which means another half do not get the time-sensitive treatment needed, which researchers believe is due to being unaware of the symptoms.
An analysis of several studies suggest that when critical life-saving skills are not frequently used by MDs, they start to lose them in as little as half a year.
A new study demonstrates the importance of eating fruits, particularly apples and blueberries, in reducing the risk of developing type 2 diabetes.
A survey of singles’ drinking habits finds that 7 of the 10 cities with the fewest heavy drinkers are in the sun belt, while among the 10 heaviest drinking cities, only one is. The lightest drinking city is Las Vegas. The heaviest is Washington, D.C..
(By CalorieLab editors)
Lab Notes: Obese Face Death Risk on Sleeping Pills; Miss America 2008 Talks About Anorexia is a post from: CalorieLab - Health News & Information Blog
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!I take it because I have ADD, but if I'm not working or in school sometimes I slack and don't get my prescription refilled as often as I should...
Read The Full Article:
http://www.obesitydiscussion.com/forums/off-topic/have-experience-adderall-weight
-loss-19485.html
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!
Powered by blogdig.net